Carboplatin in previously treated multiple myeloma. A Cancer and Leukemia Group B phase II trial.
Carboplatin in previously treated multiple myeloma. A Cancer and Leukemia Group B phase II trial.
复制标题
卡铂用于既往治疗的多发性骨髓瘤。
DOI：
10.1097/00000421-199406000-00003
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Schiffer,CA
中科院分区：
文献类型：
--
作者：
Omura,GA;Perri,RT;Peterson,B;Schiffer,CA
Carboplatin 400 mg/m 2 per month was evaluated as a single agent in 15 patients with multiple myeloma who had had one prior chemotherapy regimen. All but three were judged to have had some degree of refractoriness to prior therapy. Hematologic toxicity was frequent and sometimes severe. There were no responses. Further evaluation of standard-dose single-agent Carboplatin in refractory myeloma does not appear warranted.
塞来昔布而非罗非考昔在体外抑制转化细胞的生长
影响因子：
11.5
作者：
D. Kazanov;H. Dvory‐Sobol;M. Pick;E. Liberman;L. Strier;Efrat Choen;V. Deutsch;T. Kunik;N. Arber
通讯作者：
N. Arber
影响因子：
158.5
作者：
Steinbach, G;Lynch, PM;Kelloff, G
通讯作者：
Kelloff, G